GovChime
Notice ID: 4f79f301b75d4d79a2fd7299c78acc29Award NoticeAwarded

Duloxetine HCL DR Capsules

Awarded on July 13, 2026. Full description on SAM.gov.

Awarded tounder SPE2D2-26-D-0008 (source: SAM.gov award notice)• $133.2M

Overview

Posted
July 14, 2026
Notice type
Award Notice
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of WarDEFENSE LOGISTICS AGENCY

Notice details

Office
TROOP SUPPORT MEDICAL.DLA TROOP SUPPORT
Place of performance
Salcete, Goa, 403722
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov
Award date
Jul 13, 2026
Award amount (SAM.gov award notice)
$133.2M

Identifiers

Solicitation number
SPE2D2-26-D-0008
Notice ID
4f79f301b75d4d79a2fd7299c78acc29
Award number (PIID)
SPE2D2-26-D-0008

Description

SPE2D2-26-D-0008 Duloxetine HCL DR Award

Full description on SAM.gov

Award Overview

Award Number

SPE2D2-26-D-0008

Award Amount (SAM.gov award notice)

$133.2M

Award Date

Jul 13, 2026

Awardee

Awardee UEI

GQLDJJ8AQNN5

Awardee CAGE Code

1HT23

Awardee Address

Camarillo, CA 93012, UNITED STATES

Original Solicitation

Notice ID: 4f79f301b75d4d79a2fd7299c78acc29

Posted Date: Jul 14, 2026

Original Response Deadline: Not specified

More From This Vendor

Top 5 most recent

5
  • SPE2D326F386H
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $78.72Signed Aug 14, 2026
  • SPE2D326F373X
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $147.36Signed Aug 12, 2026
  • SPE2D326F373Z
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $535.44Signed Aug 12, 2026
  • SPE2D326F375Z
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $27.3Signed Aug 12, 2026
  • SPE2D326F359Y
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $85.96Signed Aug 10, 2026

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

Files (11)

  • SPE2D225R0010 0006 updates.pdf

    262 KBAdded in Combined Synopsis/Solicitation version 14Posted
    Download
  • SPE2D225R0010 0006 released.pdf

    145 KBAdded in Combined Synopsis/Solicitation version 14Posted
    Download
  • SPE2D225R0010 0005 released.PDF

    18 KBAdded in Combined Synopsis/Solicitation version 12Posted
    Download
  • SPE2D225R0010 0004 released.pdf

    105 KBAdded in Combined Synopsis/Solicitation version 10Posted
    Download
  • SPE2D225R0010 0003 released.pdf

    106 KBAdded in Combined Synopsis/Solicitation version 9Posted
    Download
  • Updated Schedule of Supplies P00001.pdf

    121 KBAdded in Award Notice version 4Posted
    Download
  • SPE2D225R0010 0002 released.pdf

    106 KBAdded in Combined Synopsis/Solicitation version 7Posted
    Download
  • SPE2D226D0008P00001 Bilaterally signed.pdf

    86 KBAdded in Award Notice version 4Posted
    Download
  • SPE2D225R0010 0001 released.pdf

    107 KBAdded in Combined Synopsis/Solicitation version 7Posted
    Download
  • Duloxetine - SPE2D2-26-D-0008 GSMS signed.pdf

    1000 KBAdded in Award Notice version 3Posted
    Download
  • Duloxetine HCL DR SPE2D225R0010 Solicitation release.pdf

    1.4 MBAdded in Combined Synopsis/Solicitation version 7Posted
    Download

Lifecycle

  1. 2
    Version 2Combined Synopsis/SolicitationArchived

    Duloxetine HCL DR Capsules

    Notice 316298879f4d4bdfb541499abc1d6fa5 on SAM.gov

  2. 3
    Version 3Award Notice

    Type changed from Combined Synopsis/Solicitation to Award Notice

    Duloxetine HCL DR Capsules

    Notice c6ec6b2fd58041f99af55c85f7e13635 on SAM.gov

  3. 4
    Version 4Award NoticeCurrent

    Duloxetine HCL DR Capsules

    Notice 4f79f301b75d4d79a2fd7299c78acc29 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation11/30/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
-Solicitation12/07/2026
The Defense Logistics Agency is issuing a solicitation for a national requirements contract for Epinephrine Injectors. Procurement details follow. Epinephrine 0.3 MG/0.3 ML Injection, Auto-Injector 2S in 2 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Jeremy Brown at (445) 737-5419, (jeremy.brown@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current solicitation date is October of 2026.
-Solicitation11/30/2026
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Fentanyl Citrate Injection Solution. Procurement details follow. Fentanyl (PF) 50 MCG/ML Injection Solution in 1 ML, 2 ML, 5 ML,10 ML, 20 ML and 50 ML in Vials or Ampules, Pack Size of 1, 2, 5, 10, 20, and 50. Competition will be restricted to domestic sources (vendors providing Active Pharmaceutical Ingredients (API) and Final Dosage Forms (FDF) manufactured domestically), the procurement will be competed among all qualified domestic manufacturers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of War (DoW), Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov/. Interested parties should contact Nancy Fernandez at (445) 737-0731 or Nancy.Fernandedz@dla.mil with any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is November/December of 2026. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
-Pre-SolicitationOpen
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item 0001: OXYGEN, USP, FILLED CYLINDER, SIZE D, 95GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5181 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0002: OXYGEN, USP, FILLED CYLINDER, SIZE H, 1650 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5199 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0003: NITROUS OXIDE, USP, FILLED CYLINDER, SIZE D, 250 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-130-1920 Shall be made in accordance with MIL-N-37996 DATED 24 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Medical Gas Cylinder in accordance with the Military Specifications listed above. NOTE: Only Type I-DOT 3AA STEEL Medical Gas Cylinders are acceptable. If your firm currently manufactures or distributes Type I-DOT 3AA STEEL Medical Gas Cylinders in accordance with the Military Specifications and changes attached, please provide information with respect to the following: Source and Part Number being supplied for each type of cylinder Place of manufacture for each type of cylinder Source for the Medical Gases Current unit sale price for each type of cylinder prefilled with the medical grade gas Estimated annual capacity for each type of cylinder/medical grade gas Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil
-Market Research11/15/2026

Additional Details

Solicitation Number

SPE2D2-26-D-0008

Archive Date

Jul 12, 2031

Place of Performance Country

INDIA

Office Address

PHILADELPHIA, PA, 19111